Cargando…

Advances in the pathophysiology and treatment of relapsed/refractory Hodgkin’s lymphoma with an emphasis on targeted therapies and transplantation strategies

Hodgkin’s lymphoma (HL) is highly curable with first-line therapy. However, a minority of patients present with refractory disease or experience relapse after completion of frontline treatment. These patients are treated with salvage chemotherapy followed by autologous stem cell transplantation (ASC...

Descripción completa

Detalles Bibliográficos
Autores principales: Karantanos, Theodoros, Politikos, Ioannis, Boussiotis, Vassiliki A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5502320/
https://www.ncbi.nlm.nih.gov/pubmed/28701859
http://dx.doi.org/10.2147/BLCTT.S105458
_version_ 1783248933133221888
author Karantanos, Theodoros
Politikos, Ioannis
Boussiotis, Vassiliki A
author_facet Karantanos, Theodoros
Politikos, Ioannis
Boussiotis, Vassiliki A
author_sort Karantanos, Theodoros
collection PubMed
description Hodgkin’s lymphoma (HL) is highly curable with first-line therapy. However, a minority of patients present with refractory disease or experience relapse after completion of frontline treatment. These patients are treated with salvage chemotherapy followed by autologous stem cell transplantation (ASCT), which remains the standard of care with curative potential for refractory or relapsed HL. Nevertheless, a significant percentage of such patients will progress after ASCT, and allogeneic hematopoietic stem cell transplantation remains the only curative approach in that setting. Recent advances in the pathophysiology of refractory or relapsed HL have provided the rationale for the development of novel targeted therapies with potent anti-HL activity and favorable toxicity profile, in contrast to cytotoxic chemotherapy. Brentuximab vedotin and programmed cell death-1-based immunotherapy have proven efficacy in the management of refractory or relapsed HL, whereas several other agents have shown promise in early clinical trials. Several of these agents are being incorporated with transplantation strategies in order to improve the outcomes of refractory or relapsed HL. In this review we summarize the current knowledge regarding the mechanisms responsible for the development of refractory/relapsed HL and the outcomes with current treatment strategies, with an emphasis on targeted therapies and hematopoietic stem cell transplantation.
format Online
Article
Text
id pubmed-5502320
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-55023202017-07-10 Advances in the pathophysiology and treatment of relapsed/refractory Hodgkin’s lymphoma with an emphasis on targeted therapies and transplantation strategies Karantanos, Theodoros Politikos, Ioannis Boussiotis, Vassiliki A Blood Lymphat Cancer Review Hodgkin’s lymphoma (HL) is highly curable with first-line therapy. However, a minority of patients present with refractory disease or experience relapse after completion of frontline treatment. These patients are treated with salvage chemotherapy followed by autologous stem cell transplantation (ASCT), which remains the standard of care with curative potential for refractory or relapsed HL. Nevertheless, a significant percentage of such patients will progress after ASCT, and allogeneic hematopoietic stem cell transplantation remains the only curative approach in that setting. Recent advances in the pathophysiology of refractory or relapsed HL have provided the rationale for the development of novel targeted therapies with potent anti-HL activity and favorable toxicity profile, in contrast to cytotoxic chemotherapy. Brentuximab vedotin and programmed cell death-1-based immunotherapy have proven efficacy in the management of refractory or relapsed HL, whereas several other agents have shown promise in early clinical trials. Several of these agents are being incorporated with transplantation strategies in order to improve the outcomes of refractory or relapsed HL. In this review we summarize the current knowledge regarding the mechanisms responsible for the development of refractory/relapsed HL and the outcomes with current treatment strategies, with an emphasis on targeted therapies and hematopoietic stem cell transplantation. Dove Medical Press 2017-05-09 /pmc/articles/PMC5502320/ /pubmed/28701859 http://dx.doi.org/10.2147/BLCTT.S105458 Text en © 2017 Karantanos et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
Karantanos, Theodoros
Politikos, Ioannis
Boussiotis, Vassiliki A
Advances in the pathophysiology and treatment of relapsed/refractory Hodgkin’s lymphoma with an emphasis on targeted therapies and transplantation strategies
title Advances in the pathophysiology and treatment of relapsed/refractory Hodgkin’s lymphoma with an emphasis on targeted therapies and transplantation strategies
title_full Advances in the pathophysiology and treatment of relapsed/refractory Hodgkin’s lymphoma with an emphasis on targeted therapies and transplantation strategies
title_fullStr Advances in the pathophysiology and treatment of relapsed/refractory Hodgkin’s lymphoma with an emphasis on targeted therapies and transplantation strategies
title_full_unstemmed Advances in the pathophysiology and treatment of relapsed/refractory Hodgkin’s lymphoma with an emphasis on targeted therapies and transplantation strategies
title_short Advances in the pathophysiology and treatment of relapsed/refractory Hodgkin’s lymphoma with an emphasis on targeted therapies and transplantation strategies
title_sort advances in the pathophysiology and treatment of relapsed/refractory hodgkin’s lymphoma with an emphasis on targeted therapies and transplantation strategies
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5502320/
https://www.ncbi.nlm.nih.gov/pubmed/28701859
http://dx.doi.org/10.2147/BLCTT.S105458
work_keys_str_mv AT karantanostheodoros advancesinthepathophysiologyandtreatmentofrelapsedrefractoryhodgkinslymphomawithanemphasisontargetedtherapiesandtransplantationstrategies
AT politikosioannis advancesinthepathophysiologyandtreatmentofrelapsedrefractoryhodgkinslymphomawithanemphasisontargetedtherapiesandtransplantationstrategies
AT boussiotisvassilikia advancesinthepathophysiologyandtreatmentofrelapsedrefractoryhodgkinslymphomawithanemphasisontargetedtherapiesandtransplantationstrategies